当前位置: 首页 >> 检索结果
9586. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.
作者: Tomoko Fujii.;Nora Luethi.;Paul J Young.;Daniel R Frei.;Glenn M Eastwood.;Craig J French.;Adam M Deane.;Yahya Shehabi.;Ludhmila A Hajjar.;Gisele Oliveira.;Andrew A Udy.;Neil Orford.;Samantha J Edney.;Anna L Hunt.;Harriet L Judd.;Laurent Bitker.;Luca Cioccari.;Thummaporn Naorungroj.;Fumitaka Yanase.;Samantha Bates.;Forbes McGain.;Elizabeth P Hudson.;Wisam Al-Bassam.;Dhiraj Bhatia Dwivedi.;Chloe Peppin.;Phoebe McCracken.;Judit Orosz.;Michael Bailey.;Rinaldo Bellomo.; .
来源: JAMA. 2020年323卷5期423-431页
It is unclear whether vitamin C, hydrocortisone, and thiamine are more effective than hydrocortisone alone in expediting resolution of septic shock.
9587. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial.
作者: .;Paul J Young.;Sean M Bagshaw.;Andrew B Forbes.;Alistair D Nichol.;Stephen E Wright.;Michael Bailey.;Rinaldo Bellomo.;Richard Beasley.;Kathy Brickell.;Glenn M Eastwood.;David J Gattas.;Frank van Haren.;Edward Litton.;Diane M Mackle.;Colin J McArthur.;Shay P McGuinness.;Paul R Mouncey.;Leanlove Navarra.;Dawn Opgenorth.;David Pilcher.;Manoj K Saxena.;Steve A Webb.;Daisy Wiley.;Kathryn M Rowan.
来源: JAMA. 2020年323卷7期616-626页
Proton pump inhibitors (PPIs) or histamine-2 receptor blockers (H2RBs) are often prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU). The comparative effect of these drugs on mortality is unknown.
9595. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
US law requires testing of new drugs before approval to ensure that they provide a well-defined benefit that is commensurate with their risks. A major challenge for the US Food and Drug Administration (FDA) is to achieve an appropriate balance between rigorous testing and the need for timely approval of drugs that have benefits that outweigh their risks.
9599. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
作者: Jeffrey I Weitz.;Rupert Bauersachs.;Bastian Becker.;Scott D Berkowitz.;Maria C S Freitas.;Michael R Lassen.;Carola Metzig.;Gary E Raskob.
来源: JAMA. 2020年323卷2期130-139页
The efficacy of factor XIa inhibition for thromboprophylaxis is unknown. Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa.
9600. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
作者: Karen E Hoffman.;David F Penson.;Zhiguo Zhao.;Li-Ching Huang.;Ralph Conwill.;Aaron A Laviana.;Daniel D Joyce.;Amy N Luckenbaugh.;Michael Goodman.;Ann S Hamilton.;Xiao-Cheng Wu.;Lisa E Paddock.;Antoinette Stroup.;Matthew R Cooperberg.;Mia Hashibe.;Brock B O'Neil.;Sherrie H Kaplan.;Sheldon Greenfield.;Tatsuki Koyama.;Daniel A Barocas.
来源: JAMA. 2020年323卷2期149-163页
Understanding adverse effects of contemporary treatment approaches for men with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment selection.
|